PRCT
PROCEPT BioRobotics Corporation
$29.00
+0.07
(+0.24%)
Mkt Cap
1.65B
Volume
1,119,372
52W Range
19.35-66.85
Sector
Healthcare
Beta
0.83
EPS (TTM)
-1.82
P/E Ratio
-18.28
Revenue (TTM)
322.02M
Rev Growth (5Y)
+109.1%
EPS Growth (5Y)
N/A
Company Description
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 308.05M | 224.50M | 136.19M | 75.01M | 34.47M | 7.72M | 6.17M |
| Net Income | (95.57M) | (91.41M) | (105.90M) | (87.15M) | (59.85M) | (53.02M) | (41.98M) |
| EPS | -1.72 | -1.75 | -2.24 | -1.96 | -1.37 | -1.51 | -1.25 |
| Free Cash Flow | (58.34M) | (103.62M) | (133.21M) | (83.03M) | (57.93M) | (48.58M) | (51.43M) |
| FCF / Share | -1.05 | -1.99 | -2.82 | -1.87 | -1.33 | -1.38 | -1.53 |
| Operating CF | (48.98M) | (99.21M) | (108.00M) | (80.38M) | (57.33M) | (48.34M) | (43.82M) |
| Total Assets | 508.08M | 534.02M | 404.72M | 309.33M | 337.02M | 125.97M | 61.99M |
| Total Debt | 51.62M | 80.25M | 79.20M | 77.32M | 54.10M | 54.76M | 23.22M |
| Cash & Equiv | 286.50M | 333.73M | 257.22M | 222.64M | 304.32M | 100.13M | 42.02M |
| Book Value | 365.87M | 402.22M | 280.75M | 197.07M | 267.09M | 60.96M | 29.23M |
| Return on Equity | -0.26 | -0.23 | -0.38 | -0.44 | -0.22 | -0.87 | -1.44 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83.13M | 76.38M | 83.33M | 79.18M | 69.16M | 68.24M | 58.37M | 53.35M | 44.54M | 43.58M | 35.10M | 33.10M |
| Net Income | (31.64M) | (29.84M) | (21.41M) | (19.58M) | (24.74M) | (18.86M) | (20.97M) | (25.63M) | (25.96M) | (27.50M) | (24.62M) | (25.29M) |
| EPS | -0.56 | -0.53 | -0.38 | -0.35 | -0.45 | -0.35 | -0.40 | -0.50 | -0.51 | -0.54 | -0.51 | -0.56 |
| Free Cash Flow | (41.04M) | (12.18M) | (9.50M) | (17.84M) | (18.82M) | (33.56M) | (19.05M) | (16.78M) | (34.23M) | (33.51M) | (24.72M) | (33.71M) |
| FCF / Share | -0.73 | -0.22 | -0.17 | -0.32 | -0.34 | -0.62 | -0.37 | -0.33 | -0.67 | -0.66 | -0.51 | -0.75 |
| Operating CF | (38.13M) | (10.33M) | (6.63M) | (15.04M) | (16.98M) | (32.39M) | (18.80M) | (15.74M) | (32.29M) | (24.79M) | (18.94M) | (28.34M) |
| Total Assets | 487.06M | 508.08M | 511.54M | 513.05M | 519.38M | 534.02M | 374.14M | 374.35M | 382.90M | 404.72M | 421.12M | 272.45M |
| Total Debt | 51.66M | 51.62M | 78.93M | 79.37M | 79.81M | 80.25M | 80.64M | 81.02M | 81.39M | 79.20M | 79.74M | 80.76M |
| Cash & Equiv | 245.64M | 286.50M | 294.28M | 302.72M | 316.21M | 333.73M | 196.76M | 214.09M | 225.58M | 257.22M | 287.86M | 150.47M |
| Book Value | 347.67M | 365.87M | 380.28M | 385.80M | 389.16M | 402.22M | 241.22M | 251.78M | 264.05M | 280.75M | 299.36M | 155.90M |
| Return on Equity | -0.09 | -0.08 | -0.06 | -0.05 | -0.06 | -0.05 | -0.09 | -0.10 | -0.10 | -0.10 | -0.08 | -0.16 |
PRCT News
AUA Guidelines Strengthen Recommendation for Aquablation® Therapy
PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
Chicago Capital Doubles Down on PROCEPT BioRobotics, Adds $27 Million in Stock
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz